A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 1999
This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as the colon) in patients with a history of colorectal adenomas.
Epistemonikos ID: 37d191a9bf5e4810427bdd9e1d5bbb653a726d24
First added on: May 04, 2024